RxDoctor Payments Data

Utpal Bhatt, MD

Pulmonary Disease · Bradenton, FLNPI 1649218983

Payments from drug & device makers

$1,383in general payments, 2019–2025

Across 60 payments — averaging $23.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$282
  • AbbVie$193
  • Insmed, Inc.$158
  • GSK$130
  • Boehringer Ingelheim$102
  • Harmony Biosciences LLC$96
  • plus $421 from 11 others

What the payments were for

  • Food & beverage$1,30995%
  • Education$735%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,383 in reported general payments places this provider in the 30th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$3,097
Medicare patients
26
Services billed
71

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter784$619,172
OfevNintedanib Esylate12$166,747
Breztri AerosphereBudesonide/Glycopyr/Formoterol196$145,644
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr240$129,230
Spiriva HandihalerTiotropium Bromide89$61,334
Stiolto RespimatTiotropium Br/Olodaterol Hcl56$43,668
Incruse ElliptaUmeclidinium Bromide77$36,566
Spiriva RespimatTiotropium Bromide48$34,341
SymbicortBudesonide/Formoterol Fumarate112$28,496
Breo ElliptaFluticasone/Vilanterol43$18,312
Ventolin HfaAlbuterol Sulfate247$16,681
Albuterol Sulfate HfaAlbuterol Sulfate664$15,693
Bevespi AerosphereGlycopyrrolate/Formoterol Fum24$14,940
Roflumilast100$14,324
Combivent RespimatIpratropium/Albuterol Sulfate15$11,914

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta$130$803,2801,144 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$102$256,670131 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$33$189,080332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →